Lenvatinib exerts its therapeutic effects by targeting vascular endothelial growth factor receptors 1–3, fibroblast growth factor receptors 1–4, and platelet‐derived growth factor receptor‐alpha, and enhances anti‐tumour immune responses through remodelling the tumour immunosuppressive microenvironment [3]. This evidence concerns the gene FGFR1 and neoplasm.